The week in pharma: action, reaction and insight – week to October 28, 2022
By Barbara Obstoj-Cardwell. Editor
Among significant research news last week, Swiss pharma giant Novartis announced Phase III results for its investigational drug iptacopan, demonstrating superiority to AstraZeneca’s blockbuster franchise – Solaris and Ultomiris - in the treatment of hemoglobinuria (PNH). Mirum Pharmaceuticals released new Phase III data on Livmarli, a proposed treatment for the rare pediatric disease familial intrahepatic cholestasis (PFIC). And UK pharma major GSK last Thursday revealed it is discontinuing development of the investigational drug otilimab in rheumatoid arthritis. Also of note, Johnson & Johnson’s Janssen unit last Tuesday received a second approval for its multiple myeloma drug Tecvayli, this time from the US Food and Drug Administration (FDA).
Novartis’ Solaris challenger clears the first hurdle
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze